We program mRNAs that can be read into therapeutic proteins selectively in target cells. They’re complemented by a clinically validated delivery system that drives them to the target tissue. The combined result is a novel class of therapies that are more efficacious and tolerable than standard of care.
Legacy approaches to mRNA design are poor at targeting specific cells within tissue and tumor microenvironments. Fuzzy cell selection is a key barrier to therapeutic relevance.
Selective translation is the kernel of mRNA 2.0.See how it works